Search Videos and More
Showing 1 - 6 of 6 results
News
Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Dana-Farber Cancer Center and Weill Cornell Medicine investigators and their colleagues.
News
Immunotherapy Combination Shows Significant Benefit for Patients with Advanced Melanoma
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients.
News
Benefit of Immunotherapy Combination for Patients with Advanced Melanoma Extends to Subsequent Treatment, Study Finds
A combination of two immunotherapy drugs, already shown to be more effective in patients with advanced melanoma than one of the drugs alone, also prolongs the benefit to patients who receive subsequent therapies, a clinical trial led by Dana-Farber Cancer Institute investigators indicates. The findings will be presented today at the 2021 Congress of the European Society of Medical Oncology (ESMO).
Video
Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma
Dana-Farber's Giacomo Oliveira, PhD describes a study he led with Cathy Wu, MD, that appeared in Nature.
Document
Melanoma Select Clinical Trials
The listed trials are a sampling of our many open and accruing studies.
News
Personalized Vaccine Produces Long-Lasting Anti-Tumor Response in Patients with Melanoma, Study Shows
Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study.